Data from the STEEPLE trial in patients undergoing elective PCI were used to assess the impact of hematomas > or = 5 cm on ischemic outcomes ( mortality , nonfatal myocardial infarction , or urgent target vessel revascularization ) up to day 30 and all-cause 1-year mortality .
